


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:47:43Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405542" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405542</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>scirep</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405542</article-id><article-id pub-id-type="pmcid-ver">PMC12405542.1</article-id><article-id pub-id-type="pmcaid">12405542</article-id><article-id pub-id-type="pmcaiid">12405542</article-id><article-id pub-id-type="pmid">40897746</article-id><article-id pub-id-type="doi">10.1038/s41598-025-15228-w</article-id><article-id pub-id-type="publisher-id">15228</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development and validation of a methylation-specific droplet digital PCR multiplex for lung cancer detection</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jacobsen</surname><given-names initials="CM">Cecilie Mondrup</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hjorth-Hansen</surname><given-names initials="P">Peter</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wen</surname><given-names initials="SWC">Sara Witting Christensen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Augustenas</surname><given-names initials="J">Janina</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aagaard</surname><given-names initials="MM">Mads Malik</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Varnum</surname><given-names initials="C">Claus</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hilberg</surname><given-names initials="O">Ole</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hansen</surname><given-names initials="TF">Torben Fr&#248;strup</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Andersen</surname><given-names initials="RF">Rikke Fredslund</given-names></name><address><email>rikke.fredslund.andersen@rsyd.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ey0ed83</institution-id><institution-id institution-id-type="GRID">grid.7143.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 5013</institution-id><institution>Department of Biochemistry and Immunology, Vejle Hospital, </institution><institution>University Hospital of Southern Denmark, </institution></institution-wrap>Vejle, Denmark </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ey0ed83</institution-id><institution-id institution-id-type="GRID">grid.7143.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 5013</institution-id><institution>Department of Oncology, Vejle Hospital, </institution><institution>University Hospital of Southern Denmark, </institution></institution-wrap>Vejle, Denmark </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03yrrjy16</institution-id><institution-id institution-id-type="GRID">grid.10825.3e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0728 0170</institution-id><institution>Department of Regional Health Research, </institution><institution>University of Southern Denmark, </institution></institution-wrap>Odense, Denmark </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ey0ed83</institution-id><institution-id institution-id-type="GRID">grid.7143.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 5013</institution-id><institution>Department of Pathology, Vejle Hospital, </institution><institution>University Hospital of Southern Denmark, </institution></institution-wrap>Vejle, Denmark </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ey0ed83</institution-id><institution-id institution-id-type="GRID">grid.7143.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 5013</institution-id><institution>Department of Clinical Genetics, Vejle Hospital, </institution><institution>University Hospital of Southern Denmark, </institution></institution-wrap>Vejle, Denmark </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ey0ed83</institution-id><institution-id institution-id-type="GRID">grid.7143.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 5013</institution-id><institution>Department of Orthopedic Surgery, Vejle Hospital, </institution><institution>University Hospital of Southern Denmark, </institution></institution-wrap>Vejle, Denmark </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ey0ed83</institution-id><institution-id institution-id-type="GRID">grid.7143.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 5013</institution-id><institution>Department of Medicine, Vejle Hospital, </institution><institution>University Hospital of Southern Denmark, </institution></institution-wrap>Vejle, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>32305</elocation-id><history><date date-type="received"><day>15</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>6</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="41598_2025_Article_15228.pdf"/><abstract id="Abs1"><p id="Par1">Biomarkers are increasingly used in cancer management, including lung cancer. The use of circulating tumour DNA (ctDNA) detection has attracted significant interest as a non-invasive, highly specific, and sensitive strategy. In this study, we developed and validated a methylation-specific droplet digital PCR (ddPCR) multiplex assay with five tumour-specific methylation markers identified by in silico analysis for lung cancer detection across various clinical settings. The performance of the ddPCR multiplex was validated in tissue and plasma in cohorts of healthy controls and patients with both non-metastatic and metastatic disease by examining sensitivity, specificity, and marker dynamics. Furthermore, two different cut-off methods to determine ctDNA-status and their effects on sensitivity and specificity were examined. In non-metastatic disease, the ddPCR multiplex showed ctDNA-positive rates of 38.7% and 46.8%, respectively, with the two cut-off methods. In metastatic cases, these rates increased to 70.2% and 83.0%. Higher sensitivities were observed for small cell lung cancer and squamous cell carcinoma. Analyses of longitudinal samples from patients with metastatic disease undergoing treatment indicated a potential use in prognostication and treatment guidance. We present a robust, cost-effective approach to lung cancer detection. Moving forward, its performance should be evaluated and validated in larger patient cohorts across a range of clinical scenarios, exploring its full potential.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-15228-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>ctDNA</kwd><kwd>ddPCR</kwd><kwd>Multiplex</kwd><kwd>Lung cancer</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>DNA methylation</kwd><kwd>Molecular medicine</kwd><kwd>Lung cancer</kwd><kwd>DNA</kwd><kwd>Biomarkers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par33">Lung cancer was the most prevalent cancer globally in 2022 with ~&#8201;2.5&#160;million cases<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Despite advances in treatment and emphasis on early detection, most patients are diagnosed with disseminated disease and many experience disease progression despite intensive treatment<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. It remains the leading cause of cancer-related death with ~&#8201;1.8&#160;million fatalities in 2022<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Survival outcomes are strongly influenced by the stage of disease at diagnosis, with patients having metastatic disease facing a significantly poorer prognosis<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par34">Currently, the diagnosis of lung cancer patients, detection of residual disease and progression, and monitoring of treatment response are based on clinical observations and radiological imaging, particularly computed tomography (CT) scans. However, lung cancer management is challenging due to non-specific symptoms in early stages of disease and the limitations of imaging in terms of both specificity and sensitivity in diagnosing lung cancer and detecting minimal residual disease (MRD)<sup><xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref></sup>. Given these obstacles, biomarkers have been increasingly examined as a potential alternative or as an additional modality in lung cancer care.</p><p id="Par35">Blood-based biomarkers offer several advantages, especially the minimally invasive procedure compared to tissue biopsies, which remain the golden standard. Liquid biopsies can also help address challenges such as tumour heterogeneity<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> and inaccessible tumour sites. Circulating tumour DNA (ctDNA) has been extensively studied as a promising biomarker. ctDNA is shed by solid tumours or circulating tumour cells through apoptosis, necrosis and active secretion and enables real-time cancer monitoring due to its rapid clearance from the bloodstream<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Many potential applications of ctDNA analyses in lung cancer management have been examined, including early cancer detection<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>,&#160;genomic profiling for treatment selection<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>,&#160;prognostication<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>,&#160;MRD detection<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, and monitoring of treatment response<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Additionally, the short half-life of ctDNA enables rapid adjustments in treatment when samples are drawn longitudinally<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p id="Par36">ctDNA can be differentiated from genomic DNA through tumour-specific characteristics such as mutations, copy-number and structural aberrations, and changes in methylation patterns. Aberrant DNA methylation is common in cancers and often occurs early in carcinogenesis and tumorigenesis, typically in the form of changes in methylation patterns within Cytosine-phosphate-Guanine dinucleotide (CpG) islands<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Altered methylation is highly recurrent and provides an interesting avenue for a universal ctDNA detection approach in lung cancer patients as opposed to detecting mutation profiles that are highly divergent in lung cancer patients. As an example, hypermethylation of CpGs in the <italic toggle="yes">HOXA9</italic> gene has previously shown value as a prognostic biomarker in a cohort of stage III-IV lung cancer patients<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>.</p><p id="Par37">Detection of ctDNA is hindered by the low levels in circulation. This means that sensitive and precise detection methods are necessary. Droplet digital PCR (ddPCR) is with its high sensitivity, high throughput, and relatively low cost an appealing option for ctDNA analyses<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. High sensitivity is of particular importance in patients with low tumour burden, where less ctDNA is shed<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. The inclusion of multiple markers has previously been explored with positive results as a means to increase sensitivity with quantitative PCR and with ddPCR in other cancer types<sup><xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref></sup>.</p><p id="Par38">In this study, we developed and validated a novel methylation-specific ddPCR multiplex assay consisting of assays targeting five differentially methylated regions for lung cancer detection. Four markers were identified through bioinformatics analyses of Illumina 450&#160;K methylation arrays, while the fifth (<italic toggle="yes">HOXA9)</italic> was identified in earlier studies done by our group<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Our aim was to develop a universal ctDNA detection method to aid management of lung cancer patients in various clinical settings. The method could potentially be used in all stages of lung cancer disease, from early detection of cancer to monitoring of patients during palliative treatment.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Ethics</title><p id="Par39">The samples were collected with approval from the Regional Committee on Health Ethics for Southern Denmark (S-20170063 and S-20220014) and reported to the research register of the Region of Southern Denmark (23/1852). All studies were conducted in accordance with the Declaration of Helsinki, Danish law, and European data-protection regulations. Study data were collected and managed using REDCap electronic data capture tools hosted at Vejle Hospital, University Hospital of Southern Denmark<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>.</p></sec><sec id="Sec4"><title>Tissue sample collection and processing</title><p id="Par40">Tissue samples were collected during diagnostic workup and anonymised before entering the study, while plasma samples were prospectively collected in three different cohorts (Supplemental Table <xref rid="MOESM1" ref-type="media">S1</xref>).</p><p id="Par41">Formalin-fixed paraffin-embedded (FFPE) tissue samples from primary tumours in lung cancer patients (<italic toggle="yes">n</italic>&#8201;=&#8201;20) and normal lung tissue from healthy donors (<italic toggle="yes">n</italic>&#8201;=&#8201;19) were used for analysis. All tumour and normal tissue samples were collected by biopsies or during surgery. Furthermore, FFPE tissue samples were collected from patients with benign lung disease (communicable or autoimmune-related diseases, <italic toggle="yes">n</italic>&#8201;=&#8201;20). Benign tissue sampling was done by transthoracic needle biopsy or during endobronchial ultrasound bronchoscopy.</p><p id="Par42">DNA was extracted from paraffin-embedded tissue on Maxwell RSC (Promega, Madison, WI, USA) with the Maxwell FFPE Plus DNA Kit (Promega) according to the manufacturer&#8217;s instructions. DNA was eluted in 50&#160;&#181;l nuclease-free water.</p></sec><sec id="Sec5"><title>Blood sample collection and processing</title><p id="Par43">Whole blood samples from 40 patients from the Respiratory Medicine outpatient clinic and 20 patients from the Department of Orthopaedic Surgery were drawn in 9&#160;ml EDTA blood collection tubes. All patients were without known cancer and of similar age as the lung cancer patients. Similarly, whole blood samples from 109 patients with lung cancer were collected at the time of diagnosis. Patients were divided into two groups: non-metastatic (stage I-III) and metastatic (stage IV). Finally, whole blood samples were collected from 28 non-small cell lung cancer (NSCLC) patients treated with immunotherapy, with a baseline sample taken before the first treatment cycle, a second sample before the second treatment cycle, and a third sample taken before the fourth treatment cycle. After collection, EDTA tubes were centrifuged at 2,000&#160;g for 10&#160;min within 4&#160;h of venepuncture before isolation of the plasma. Plasma was stored at -80&#160;&#176;C.</p><p id="Par44">Four ml of plasma was thawed at 5&#160;&#176;C and centrifuged at 10,000&#160;g for 10&#160;min. ~9000 copies/ml of an exogenous spike-in DNA fragment (CPP1) was added to the plasma before extraction<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Cell-free DNA (cfDNA) was extracted using the DSP Circulating DNA Kit (Qiagen, Hilden Germany) on QIAsymphony SP (Qiagen) according to the manufacturer&#8217;s instructions. cfDNA was eluted in 60&#160;&#181;l QIAsymphony Plasma Elution Buffer.</p></sec><sec id="Sec6"><title>Identification of lung cancer-specific methylation sites using illumina 450&#160;K methylation arrays</title><p id="Par45">All data used for this analysis came from publicly available datasets from Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA) arrays. The samples from The Cancer Genome Atlas (TCGA) consisted of lung adjacent normal (LAN) and lung tumour (LT) samples from lung adenocarcinoma (LUAD, LAN&#8201;=&#8201;32 and LT&#8201;=&#8201;471) and lung squamous cell carcinoma (LUSC, LAN&#8201;=&#8201;42 and LT&#8201;=&#8201;370). In addition, selected previously published and publicly available datasets were used<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE67393">GSE67393</ext-link><sup><xref ref-type="bibr" rid="CR25">25</xref></sup> (peripheral blood, <italic toggle="yes">n</italic>&#8201;=&#8201;117) and <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE121192">GSE121192</ext-link><sup><xref ref-type="bibr" rid="CR26">26</xref></sup> (peripheral blood monocytes, <italic toggle="yes">n</italic>&#8201;=&#8201;16). The dataset used totalled 1048 samples, consisting of 841 lung tumour samples and 207 samples from either normal lung tissue or normal leukocytes and peripheral blood monocytes (blood normal). All TCGA data were downloaded from the NCI Genomic Data Commons (GDC) data portal<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> as of April 2020.</p><p id="Par46">All data analyses were performed in R (v. 4.0.5) using the packages <italic toggle="yes">caret</italic> (v.6.0&#8211;92), <italic toggle="yes">randomForest</italic> (v. 4.6&#8211;14), <italic toggle="yes">mlbench</italic> (v. 2.1-3), <italic toggle="yes">pheatmap</italic> (v. 1.0.12), <italic toggle="yes">ggplot2</italic> (v.3.3.5), <italic toggle="yes">dplyr</italic> (v. 1.0.7), <italic toggle="yes">readr</italic> (v.2.1.2) and <italic toggle="yes">minfi</italic><sup><xref ref-type="bibr" rid="CR28">28</xref></sup> in addition to functions in base packages.</p><p id="Par47">Methylation probes with missing values were filtered out. Mean beta-values for all lung tumour samples (<italic toggle="yes">n</italic>&#8201;=&#8201;841) and all normal samples (<italic toggle="yes">n</italic>&#8201;=&#8201;207) were calculated. An initial list of differentially methylated CpGs (DMC) was extracted by selecting sites with mean beta-value differences&#8201;&gt;&#8201;0.5 between tumour and normal samples. In addition, only DMCs mapping to CpG islands were included. Twenty-six DMCs passed this initial analysis. Recursive feature elimination (RFE) using 10-fold cross-validation (repeated 5 times) was used to identify the DMCs best suited to separate lung tumours, non-cancerous tissue, and blood normal samples (Supplemental Table S2).</p></sec><sec id="Sec7"><title>ddPCR analysis</title><p id="Par48">Four quality control parameters were examined for all plasma samples. Extraction efficiency was evaluated with a ddPCR assay targeting CPP1. Potential contamination with lymphocyte DNA was assessed using an immunoglobulin gene-specific ddPCR assay (PBC)<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Total cfDNA concentration and contamination with high-molecular-weight DNA were evaluated with ddPCR assays amplifying a 65&#160;bp and 250&#160;bp region of the <italic toggle="yes">EMC7</italic> gene<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. <italic toggle="yes">EMC7 65</italic> was used as a measure of total cfDNA concentration. A genomic DNA control sample from whole blood with added CPP1 was used as a positive control for quality control assays.</p><p id="Par49">The extracted DNA was concentrated to 20&#160;&#181;l with an Amicon Ultra-0.5 Centrifugal Filter unit (Merck, Darmstadt, Germany) and bisulfite converted using the EZ DNA Methylation-Lightning Kit (Zymo Research, Irvine, CA, USA). Bisulfite-converted DNA was eluted with 15&#160;&#181;l M-Elution Buffer. DNA from plasma and tissue samples was analysed using the Bio-Rad QX600 Droplet Digital PCR system (Bio-Rad, Hercules, CA, USA). In brief, the 20&#160;&#181;l ddPCR reaction consisted of 2x ddPCR Supermix for Probes (No dUTP) (Bio-Rad), probes and primers, and 5&#160;&#181;l template DNA (Supplemental Table S3). Each plate included a non-template control and two negative controls: genomic DNA and cfDNA isolated from a plasma pool from non-cancer patients. The methylation analyses also included Universal Methylated Human DNA Standard (Zymo Research) as a positive control. All control samples were analysed in parallel with patient samples. Methylation-specific ddPCR analyses were run in duplicates. Droplets were generated using an Automated Droplet Generator (Bio-Rad). The PCR was performed on a Veriti&#8482; Thermal Cycler (Applied Biosystems, Waltham, MA, USA) with the following PCR conditions: 95&#160;&#176;C for 10&#160;min, 44 cycles of 95&#160;&#176;C for 15&#160;s and 56&#160;&#176;C for 1&#160;min, and 98&#160;&#176;C for 10&#160;min using a 2&#160;&#176;C/s ramp rate. The plates were read on a QX600 Droplet Reader (Bio-Rad).</p></sec><sec id="Sec8"><title>Design and testing of ddPCR multiplex</title><p id="Par50">Primers and probes were designed using the Bisulfite Primer Design Tool (Zymo Research) and the PrimerQuest Tool (Integrated DNA Technologies, Coralville, IA, USA) and tested using the BiSearch Primer Search Tool<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Primers were designed to generate amplicons&#8201;&lt;&#8201;100&#160;bp.</p><p id="Par51">Identified assays targeting methylated CpG sites were initially tested in duplexes with the reference gene, albumin (<italic toggle="yes">ALB</italic>), on whole blood samples from healthy donors and Universal Methylated Human DNA Standard (Zymo Research). Assays showing excessive rain on fluorescence plots, positive droplets in samples from healthy donors, or no positive droplets in the hypermethylated control were excluded from further testing. Next, lung tumour and normal lung tissue were analysed with the remaining assays in duplexes with <italic toggle="yes">ALB</italic>. Assays showing the greatest difference in methylation ratio between tumour and normal tissue were selected for a multiplex ddPCR. An additional marker, <italic toggle="yes">HOXA9</italic>, was identified in the literature and used in earlier studies on ctDNA detection in lung cancer patients.</p><p id="Par52">Five selected assays (named by nearest genes; <italic toggle="yes">HOXA9</italic>,<italic toggle="yes"> OTX1</italic>,<italic toggle="yes"> MCIDAS</italic>,<italic toggle="yes"> SP9</italic>, and <italic toggle="yes">TFAP2B)</italic> were combined with <italic toggle="yes">ALB</italic> in a 6-plex ddPCR. Subsequently, a six-point 2-fold dilution series of bisulfite converted DNA from a Universal Methylated Human DNA Standard (Zymo Research) in a constant background of 5600 copies of genomic DNA was analysed individually for each marker in duplex with <italic toggle="yes">ALB</italic> and in the combined 6-plex ddPCR. All analyses were run in duplicates.</p><p id="Par53">DNA extracted from lung tumour tissue was tested with the 6-plex ddPCR. Furthermore, normal lung tissue and tissue from patients with non-cancer lung disease were analysed and compared with tumour tissue.</p></sec><sec id="Sec9"><title>Plasma sample analysis</title><p id="Par54">Limit of blank (LoB) based on the number of positive droplets was determined by analysing plasma samples from 60 healthy controls. LoB was determined for each marker in two different ways: as the highest number of positive droplets for negative samples with a set specificity of &#8805;&#8201;95% and using Youden&#8217;s J statistics<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. For Youden&#8217;s J statistics, non-metastatic (i.e. stage I-III) from the lung cancer patient cohort (<italic toggle="yes">n</italic>&#8201;=&#8201;62) were used as positive cases.</p><p id="Par55">The clinical sensitivity and specificity of the combined 6-plex ddPCR were examined in a cohort of 109 patients with lung cancer, including UICC stage I-IV patients. Finally, the dynamics of the five markers were examined in a cohort of 28 NSCLC patients treated with immunotherapy.</p></sec><sec id="Sec10"><title>Data analysis</title><p id="Par56">All data from the QX600 Droplet Reader was analysed with QXManager Software 2.0 (Bio-Rad). The number of positive droplets, concentrations (copies/&#181;l), ratios (marker/<italic toggle="yes">ALB</italic>), and confidence intervals (CI) were used to interpret the performance of each marker. Pearson&#8217;s correlation coefficient was calculated to compare the linearity of the assays in duplex with <italic toggle="yes">ALB</italic> and in the combined 6-plex ddPCR. Kruskall-Wallis and Mann-Whitney U-tests were used to compare methylation levels in tissues. All tests were two-sided; p-values&#8201;&lt;&#8201;0.05 were considered statistically significant. The dynamics of each marker were evaluated by ratio and Poisson CI. Increases and decreases in methylation ratios for each marker was assessed according to ctDNA RECIST, as previously described<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. All statistical and graphical analyses were performed using R (v. 4.3.1) using the packages <italic toggle="yes">OptimalCutpoint</italic> (v. 1.1.5), <italic toggle="yes">ggpubr</italic> (v. 0.6.0), <italic toggle="yes">survminer</italic> (v. 0.5.0), and <italic toggle="yes">ggplot2</italic> (v. 3.5.1) in addition to functions in base packages.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>In-silico identification of differentially methylated sites</title><p id="Par57">Twenty-six DMCs were identified as being differentially methylated in lung cancer tissue compared to normal lung tissue and blood. Differences in mean beta-values were between 0.50 and 0.60, and mean beta-values for the 26 sites in the tumour samples were 0.54&#8211;0.75 and 0.03&#8211;0.21 in the normal samples (Supplemental Table S2).</p><p id="Par58">Specifically, the four sites included in the final multiplex had the following mean beta-values and standard deviations in tumour samples: <italic toggle="yes">OTX1</italic>, 0.59 (0.19); <italic toggle="yes">MCIDAS</italic>, 0.57 (0.26); <italic toggle="yes">SP9</italic>, 0.60 (0.22); and <italic toggle="yes">TFAP2B</italic>, 0.69 (0.20).</p></sec><sec id="Sec13"><title>Design and initial test of assays</title><p id="Par59">Assays were designed for all 26 DMCs identified in the in-silico analyses. All assays were first tested on hypermethylated controls and genomic DNA from healthy donors. Next, lung tumour and normal lung tissue were tested with each marker to ensure assay positivity in tumour tissue. The selection process resulted in a 6-plex ddPCR with five lung cancer-specific assays (<italic toggle="yes">HOXA9</italic>,<italic toggle="yes"> OTX1</italic>,<italic toggle="yes"> MCIDAS</italic>,<italic toggle="yes"> SP9</italic>, and <italic toggle="yes">TFAP2B</italic>) and one reference assay, <italic toggle="yes">ALB</italic> (Supplemental Figure <xref rid="MOESM1" ref-type="media">S1</xref>). Cluster position and background levels were visually inspected to ensure no cross-reactions between the selected assays.</p></sec><sec id="Sec14"><title>Linearity of 6-plex ddPCR</title><p id="Par60">The five selected assays were tested in a duplex with <italic toggle="yes">ALB</italic> and in the combined 6-plex ddPCR in a six-point dilution series to ensure correlation in performance. Calculation of Pearson correlation coefficient showed no significant difference between the expected ratios and the measured ratios for any of the five assays, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par61">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Linearity of 6-plex ddPCR. Linear correlation between expected and measured methylation ratios for each assay in a six-point two-fold dilution of Universal Methylated Human DNA Standard (Zymo Research) in a constant background of 5600 copies of bisulfite-converted genomic DNA from whole blood. (<bold>a)</bold>
<italic toggle="yes">HOXA9</italic>, (<bold>b)</bold>
<italic toggle="yes">MCIDAS</italic>, (<bold>c)</bold>
<italic toggle="yes">OTX1</italic>, (<bold>d)</bold>
<italic toggle="yes">SP9</italic>, and (<bold>e)</bold>
<italic toggle="yes">TFAP2B</italic> were all tested in duplex with <italic toggle="yes">ALB</italic> and in the 6-plex ddPCR.</p></caption><graphic id="d33e876" position="float" orientation="portrait" xlink:href="41598_2025_15228_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec15"><title>Tissue analysis</title><p id="Par62">Lung tumour and normal lung tissue were tested with the selected 6-plex ddPCR. Additionally, tissue from patients with benign lung disease was tested. All five selected markers showed a statistically significant difference between normal and non-cancer tissue compared to tumour tissue (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). No significant difference was observed between normal and non-cancer tissue. Of note, several non-cancer samples exhibited a high methylation ratio of <italic toggle="yes">OTX1</italic> compared with normal tissue samples (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>c).</p><p id="Par63">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Methylation levels of the five cancer-specific markers included in the 6-plex ddPCR in normal, benign, and lung tumour tissue. Boxplots show the ratio of detected copies/&#181;l of each marker, (<bold>a)</bold>
<italic toggle="yes">HOXA9</italic>, (<bold>b)</bold>
<italic toggle="yes">MCIDAS</italic>, (<bold>c)</bold>
<italic toggle="yes">OTX1</italic>, (<bold>d)</bold>
<italic toggle="yes">SP9</italic>, and (<bold>e)</bold>
<italic toggle="yes">TFAP2B</italic>, and the reference gene (<italic toggle="yes">ALB</italic>). The statistical significance between each group was defined using Mann-Whitney U tests (ns: <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05, *: <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05, **: <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.01, ***: <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001, ****: <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.0001).</p></caption><graphic id="d33e950" position="float" orientation="portrait" xlink:href="41598_2025_15228_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec16"><title>Determination of limit of blank</title><p id="Par64">LoB was determined by analysis of 60 plasma samples from non-cancer patients with two different methods for later comparisons: a set specificity of &#8805;&#8201;95% for each marker and using Youden&#8217;s J statistics. With the first method, LoBs of 3 positive droplets for <italic toggle="yes">HOXA9</italic> and <italic toggle="yes">MCIDAS</italic>, 4 positive droplets for <italic toggle="yes">OTX1</italic> and <italic toggle="yes">SP9</italic>, and 2 positive droplets for <italic toggle="yes">TFAP2B</italic> were identified (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Using Youden&#8217;s J statistics LoBs of 1 positive droplet for <italic toggle="yes">HOXA9</italic>, 6 positive droplets for <italic toggle="yes">MCIDAS</italic>, 4 positive droplets for <italic toggle="yes">OTX1</italic>, 1 positive droplet for <italic toggle="yes">SP9</italic>, and 3 positive droplets for <italic toggle="yes">TFAP2B</italic> were identified (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par65">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Limit of blank in plasma from non-cancer patients (<italic toggle="yes">n</italic>&#8201;=&#8201;60). Limit of blank were set for (<bold>a)</bold>
<italic toggle="yes">HOXA9</italic>, (<bold>b)</bold>
<italic toggle="yes">MCIDAS</italic>, (<bold>c)</bold>
<italic toggle="yes">OTX1</italic>, (<bold>d)</bold>
<italic toggle="yes">SP9</italic>, and (<bold>e)</bold>
<italic toggle="yes">TFAP2B</italic> using two different methods: a set&#8201;&#8805;&#8201;95% specificity for each marker (blue dashed line) and with Youden&#8217;s J statistics (red dashed line).</p></caption><graphic id="d33e1037" position="float" orientation="portrait" xlink:href="41598_2025_15228_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec17"><title>Clinical sensitivity of 6-plex ddPCR</title><p id="Par66">To assess the clinical sensitivity, plasma samples from 109 patients diagnosed with lung cancer were analysed with the 6-plex ddPCR. Using the established LoBs based on a set&#8201;&#8805;&#8201;95% specificity and Youden&#8217;s J statistics, the sensitivity was determined when varying the number of markers above LoB to classify a sample as ctDNA-positive (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). For both methods, an increased number of markers required to classify a sample as ctDNA-positive resulted in lower sensitivities and higher specificities (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Generally, Youden&#8217;s J statistics resulted in higher sensitivities and lower specificities compared with LoBs based on a set&#8201;&#8805;&#8201;95% specificity (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). A cutoff&#8201;&#8805;&#8201;2 markers above LoB was chosen as the best balance of higher sensitivity without sacrificing specificity. Given the higher methylation level of <italic toggle="yes">OTX1</italic> in benign lung tissue compared to normal tissue, and the elevated droplet counts observed in three healthy controls, the diagnostic performance of a 5-plex ddPCR assay excluding <italic toggle="yes">OTX1</italic> was examined (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Omitting <italic toggle="yes">OTX1</italic> only led to a slight decrease in sensitivity and increase in specificity across both cut-off methods.</p><p id="Par67">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Percentage of ctDNA-positive non-cancer patients (<italic toggle="yes">n</italic>&#8201;=&#8201;60) and cancer patients with non-metastatic (<italic toggle="yes">n</italic>&#8201;=&#8201;62) or metastatic disease (<italic toggle="yes">n</italic>&#8201;=&#8201;47) according to the number of markers above established limits of blanks (LoB) with (<bold>a)</bold> a set of &#8805;&#8201;95% specificity and (<bold>b)</bold> Youden&#8217;s J statistics.</p></caption><graphic id="d33e1089" position="float" orientation="portrait" xlink:href="41598_2025_15228_Fig4_HTML.jpg"/></fig>
</p><p id="Par68">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Calculated sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of the 6-plex ddPCR and 5-plex ddPCR excl. OTX1 with LoBs based on a set&#8201;&#8805;&#8201;95% specificity and Youden&#8217;s J statistics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="5" rowspan="1">&#8805;&#8201;95% specificity</th><th align="left" colspan="5" rowspan="1">Youden&#8217;s J statistics</th></tr><tr><th align="left" colspan="1" rowspan="1">&#8805;&#8201;1 marker</th><th align="left" colspan="1" rowspan="1">&#8805;&#8201;2 markers</th><th align="left" colspan="1" rowspan="1">&#8805;&#8201;3 markers</th><th align="left" colspan="1" rowspan="1">&#8805;&#8201;4 markers</th><th align="left" colspan="1" rowspan="1">5 markers</th><th align="left" colspan="1" rowspan="1">&#8805;&#8201;1 marker</th><th align="left" colspan="1" rowspan="1">&#8805;&#8201;2 markers</th><th align="left" colspan="1" rowspan="1">&#8805;&#8201;3 markers</th><th align="left" colspan="1" rowspan="1">&#8805;&#8201;4 markers</th><th align="left" colspan="1" rowspan="1">5 markers</th></tr></thead><tbody><tr><td align="left" colspan="11" rowspan="1">6-plex ddPCR</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td align="left" colspan="1" rowspan="1">66.97</td><td align="left" colspan="1" rowspan="1">52.29</td><td align="left" colspan="1" rowspan="1">46.79</td><td align="left" colspan="1" rowspan="1">36.70</td><td align="left" colspan="1" rowspan="1">22.94</td><td align="left" colspan="1" rowspan="1">82.57</td><td align="left" colspan="1" rowspan="1">62.39</td><td align="left" colspan="1" rowspan="1">49.54</td><td align="left" colspan="1" rowspan="1">38.53</td><td align="left" colspan="1" rowspan="1">18.35</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td align="left" colspan="1" rowspan="1">88.33</td><td align="left" colspan="1" rowspan="1">95.00</td><td align="left" colspan="1" rowspan="1">100.00</td><td align="left" colspan="1" rowspan="1">100.00</td><td align="left" colspan="1" rowspan="1">100.00</td><td align="left" colspan="1" rowspan="1">58.33</td><td align="left" colspan="1" rowspan="1">90.00</td><td align="left" colspan="1" rowspan="1">95.00</td><td align="left" colspan="1" rowspan="1">98.33</td><td align="left" colspan="1" rowspan="1">100.00</td></tr><tr><td align="left" colspan="1" rowspan="1">PPV</td><td align="left" colspan="1" rowspan="1">91.25</td><td align="left" colspan="1" rowspan="1">95.00</td><td align="left" colspan="1" rowspan="1">100.00</td><td align="left" colspan="1" rowspan="1">100.00</td><td align="left" colspan="1" rowspan="1">100.00</td><td align="left" colspan="1" rowspan="1">78.26</td><td align="left" colspan="1" rowspan="1">91.89</td><td align="left" colspan="1" rowspan="1">94.74</td><td align="left" colspan="1" rowspan="1">97.67</td><td align="left" colspan="1" rowspan="1">100.00</td></tr><tr><td align="left" colspan="1" rowspan="1">NPV</td><td align="left" colspan="1" rowspan="1">59.55</td><td align="left" colspan="1" rowspan="1">52.29</td><td align="left" colspan="1" rowspan="1">50.85</td><td align="left" colspan="1" rowspan="1">46.51</td><td align="left" colspan="1" rowspan="1">41.67</td><td align="left" colspan="1" rowspan="1">64.81</td><td align="left" colspan="1" rowspan="1">56.84</td><td align="left" colspan="1" rowspan="1">50.89</td><td align="left" colspan="1" rowspan="1">46.83</td><td align="left" colspan="1" rowspan="1">40.27</td></tr><tr><td align="left" colspan="1" rowspan="1">Accuracy</td><td align="left" colspan="1" rowspan="1">74.56</td><td align="left" colspan="1" rowspan="1">67.46</td><td align="left" colspan="1" rowspan="1">65.68</td><td align="left" colspan="1" rowspan="1">59.17</td><td align="left" colspan="1" rowspan="1">50.30</td><td align="left" colspan="1" rowspan="1">73.96</td><td align="left" colspan="1" rowspan="1">72.19</td><td align="left" colspan="1" rowspan="1">65.68</td><td align="left" colspan="1" rowspan="1">59.76</td><td align="left" colspan="1" rowspan="1">47.34</td></tr><tr><td align="left" colspan="11" rowspan="1">5-plex ddPCR excl. <italic toggle="yes">OTX1</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td align="left" colspan="1" rowspan="1">59.63</td><td align="left" colspan="1" rowspan="1">49.54</td><td align="left" colspan="1" rowspan="1">38.53</td><td align="left" colspan="1" rowspan="1">23.85</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">77.98</td><td align="left" colspan="1" rowspan="1">60.55</td><td align="left" colspan="1" rowspan="1">40.37</td><td align="left" colspan="1" rowspan="1">19.27</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td align="left" colspan="1" rowspan="1">90.00</td><td align="left" colspan="1" rowspan="1">98.33</td><td align="left" colspan="1" rowspan="1">100.00</td><td align="left" colspan="1" rowspan="1">100.00</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">60.00</td><td align="left" colspan="1" rowspan="1">90.00</td><td align="left" colspan="1" rowspan="1">98.33</td><td align="left" colspan="1" rowspan="1">98.33</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">PPV</td><td align="left" colspan="1" rowspan="1">91.55</td><td align="left" colspan="1" rowspan="1">98.18</td><td align="left" colspan="1" rowspan="1">100.00</td><td align="left" colspan="1" rowspan="1">100.00</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">77.98</td><td align="left" colspan="1" rowspan="1">91.67</td><td align="left" colspan="1" rowspan="1">97.78</td><td align="left" colspan="1" rowspan="1">95.45</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">NPV</td><td align="left" colspan="1" rowspan="1">55.10</td><td align="left" colspan="1" rowspan="1">51.75</td><td align="left" colspan="1" rowspan="1">47.24</td><td align="left" colspan="1" rowspan="1">41.96</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">60.00</td><td align="left" colspan="1" rowspan="1">55.67</td><td align="left" colspan="1" rowspan="1">47.58</td><td align="left" colspan="1" rowspan="1">40.14</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Accuracy</td><td align="left" colspan="1" rowspan="1">70.41</td><td align="left" colspan="1" rowspan="1">66.86</td><td align="left" colspan="1" rowspan="1">60.36</td><td align="left" colspan="1" rowspan="1">50.89</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">71.60</td><td align="left" colspan="1" rowspan="1">71.01</td><td align="left" colspan="1" rowspan="1">60.95</td><td align="left" colspan="1" rowspan="1">47.34</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table></table-wrap>
</p><p id="Par69">Potential variation in detection rates for patients with different histological subtypes was also examined using both &#8805;&#8201;95% specificity LoBs (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>a) and Youden&#8217;s J statistics LoBs (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>b). The highest detection rate was observed in patients with small cell lung cancer (SCLC), where all or almost all samples were ctDNA-positive: 8/9 (88.9%) with &#8805;&#8201;95% specificity LoBs and 9/9 (100%) with Youden&#8217;s J statistics LoBs. For squamous cell carcinoma (SCC) and adenocarcinoma (AC), the detection rates were 53.9% (14/26) and 49.2% (32/65), respectively. These numbers increased to 57.7% (15/26) and 60% (39/65) when using Youden&#8217;s J statistics. Interestingly, when looking only at the patients with metastatic disease, a higher proportion of SCC was detected than AC. This was the case using both threshold methods (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>a-b).</p><p id="Par70">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Percentage of ctDNA-positive cancer patients with non-metastatic (<italic toggle="yes">n</italic>&#8201;=&#8201;62) or metastatic disease (<italic toggle="yes">n</italic>&#8201;=&#8201;47) according to histological subtypes above established limits of blanks (LoBs) with (<bold>a)</bold> a set of &#8805;&#8201;95% specificity and (<bold>b)</bold> Youden&#8217;s J statistics. Samples were considered ctDNA positive if they had&#8201;&#8805;&#8201;2 markers above LoB. SCC: squamous cell carcinoma, AC: adenocarcinoma, SCLC: small cell lung cancer. Other includes low differentiated carcinomas, carcinoid tumours, large cell neuroendocrine carcinomas, and sarcomatoid carcinomas.</p></caption><graphic id="d33e1403" position="float" orientation="portrait" xlink:href="41598_2025_15228_Fig5_HTML.jpg"/></fig>
</p></sec><sec id="Sec18"><title>Marker dynamics in longitudinal sampling</title><p id="Par71">The dynamics of the markers were examined by analysing longitudinally drawn plasma samples from 30 patients undergoing treatment with immunotherapy. Most patients had locally advanced or metastatic disease (Supplemental Table <xref rid="MOESM1" ref-type="media">S1</xref>). Droplet cut-offs established with Youden&#8217;s J statistics were used to determine whether samples were ctDNA-positive or negative. These cut-offs were selected as a higher sensitivity was preferred in the analyses of samples from patients with advanced disease undergoing treatment. Five patients only had samples collected at baseline and after the first treatment cycle. 93% (26/28) of the patients had ctDNA-positive samples at baseline (Supplemental Table S4). 61% (17/28) of the patients were ctDNA-positive at all samplings (Supplemental Table S4).</p><p id="Par72">The congruence between the markers in each sample was examined. For 32/79 samples, the status for all markers was the same (i.e. all markers were above or below their respective LoBs) (Supplemental Table S4). 8/79 samples were ctDNA-positive with only two positive markers. In all but one case, <italic toggle="yes">HOXA9</italic> and <italic toggle="yes">SP9</italic> were the two positive markers. <italic toggle="yes">TFAP2B</italic> diverged the most from the other markers, with 37/79 ctDNA-positive samples being <italic toggle="yes">TFAP2B</italic>-negative.</p><p id="Par73">Next, changes in the methylation ratio of each marker during treatment were examined by comparing Poisson CI at different time points (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). A significant increase or decrease in the methylation level of a marker was identified if there was no overlap of the CI for the values from two samples. While the five markers did show discrepancies in changes in methylation ratios, no patients exhibited both significantly increasing and decreasing methylation ratios for any of the five markers between samples. 7/28 patients became ctDNA-negative after one treatment cycle, while 2/28 patients became ctDNA-negative after three treatment cycles (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Of the three patients ctDNA-negative at baseline, two were ctDNA-positive after three treatment cycles (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par74">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Description of marker changes from baseline to 2nd treatment cycle and 4th treatment cycle according to ctDNA-RECIST criteria. LoBs were based on Youden&#8217;s J statistics, and samples were considered ctDNA positive (+) if they had&#8201;&#8805;&#8201;2 markers above the LoB. Empty fields represent missing samples. &#8595;: significant decrease, &#8593;: significant increase, &#8596;: insignificant decrease or increase. na: not applicable as the marker was negative. Empty fields indicate missing samples.</p></caption><graphic position="anchor" id="d33e1445" orientation="portrait" xlink:href="41598_2025_15228_Tab2_HTML.jpg"/></table-wrap>
</p><p id="Par75">Differences in progression-free survival (PFS) and overall survival (OS) were examined by dividing patients into three groups according to changes in methylation ratios between samples (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). <italic toggle="yes">Stable</italic> included patients with insignificant changes or where &lt;&#8201;5 markers showed a significant decrease. The patients were defined as having stable values. <italic toggle="yes">Decrease</italic> consisted of patients with significant decreases in all markers, while <italic toggle="yes">Increase</italic> consisted of patients with a significant increase in at least one marker (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). Log-rank test comparisons were performed between the different groups. A longer PFS and OS were observed in patients experiencing a significant decrease in methylation ratio in all markers (i.e. <italic toggle="yes">Decrease</italic>) compared to patients with a significant increase (i.e. <italic toggle="yes">Increase</italic>) from baseline to fourth treatment (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0041 and <italic toggle="yes">p</italic>&#8201;=&#8201;0.037, respectively) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). For all other sample time points and patient groups, no statistical differences were observed, although there was a trend toward longer PFS and OS for patients with significant decreases in methylation ratios (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>).</p><p id="Par76">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Kaplan-Meier plots showing survival curves of NSCLC patients undergoing immunotherapy according to ctDNA status. Patients were divided into three groups: <italic toggle="yes">Stable</italic>, consisting of patients with insignificant changes or where &lt;&#8201;5 markers showed a significant decrease. <italic toggle="yes">Decrease</italic>, consisting of patients with significant decreases in all markers, and <italic toggle="yes">Increase</italic>, consisting of patients with a significant increase in at least one marker. <bold>(a)</bold> Progression-free survival and (<bold>b)</bold> overall survival of patients based on change from baseline to the 2nd treatment cycle. (<bold>c)</bold> Progression-free survival and (<bold>d)</bold> overall survival of patients based on changes from baseline to the 4th treatment cycle.</p></caption><graphic id="d33e1514" position="float" orientation="portrait" xlink:href="41598_2025_15228_Fig6_HTML.jpg"/></fig>
</p><p id="Par77">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Log-rank tests comparing progression-free survival and overall survival of NSCLC patients divided into three groups: <italic toggle="yes">Stable</italic>, consisting of patients with insignificant changes or where &lt;&#8201;5 markers showed a significant decrease, <italic toggle="yes">Decrease</italic>, consisting of patients with significant decreases in all markers, and <italic toggle="yes">Increase</italic>, consisting of patients with a significant increase in at least one marker.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="left" colspan="4" rowspan="1">Baseline to 2nd treatment</th><th align="left" colspan="4" rowspan="1">Baseline to 4th treatment</th></tr><tr><th align="left" colspan="2" rowspan="1">PFS</th><th align="left" colspan="2" rowspan="1">OS</th><th align="left" colspan="2" rowspan="1">PFS</th><th align="left" colspan="2" rowspan="1">OS</th></tr><tr><th align="left" colspan="1" rowspan="1">Median<break/>(95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">Median<break/>(95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">Median<break/>(95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">Median<break/>(95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Stable</td><td align="left" colspan="1" rowspan="1">4.3 (2.9 - NR)</td><td char="." align="char" rowspan="2" colspan="1">0.23</td><td align="left" colspan="1" rowspan="1">10.8 (7.6&#8211;18.9)</td><td char="." align="char" rowspan="2" colspan="1">0.14</td><td align="left" colspan="1" rowspan="1">6.7 (4.1 - NR)</td><td char="." align="char" rowspan="2" colspan="1">0.059</td><td align="left" colspan="1" rowspan="1">16.6 (7.7 - NR)</td><td char="." align="char" rowspan="2" colspan="1">0.18</td></tr><tr><td align="left" colspan="1" rowspan="1">Decrease</td><td align="left" colspan="1" rowspan="1">11.1 (5.3 - NR)</td><td align="left" colspan="1" rowspan="1">25.7 (10.9 - NR)</td><td align="left" colspan="1" rowspan="1">19.0 (11.0 - NR)</td><td align="left" colspan="1" rowspan="1">26.3 (25.1 - NR)</td></tr><tr><td align="left" colspan="1" rowspan="1">Stable</td><td align="left" colspan="1" rowspan="1">4.3 (2.9 - NR)</td><td char="." align="char" rowspan="2" colspan="1">0.23</td><td align="left" colspan="1" rowspan="1">10.8 (7.6&#8211;18.9)</td><td char="." align="char" rowspan="2" colspan="1">0.096</td><td align="left" colspan="1" rowspan="1">6.7 (4.1 - NR)</td><td char="." align="char" rowspan="2" colspan="1">0.059</td><td align="left" colspan="1" rowspan="1">16.6 (7.7 - NR)</td><td char="." align="char" rowspan="2" colspan="1">0.59</td></tr><tr><td align="left" colspan="1" rowspan="1">Increase</td><td align="left" colspan="1" rowspan="1">2.7 (2.7 - NR)</td><td align="left" colspan="1" rowspan="1">3.4 (3.3 - NR)</td><td align="left" colspan="1" rowspan="1">3.4 (2.7 - NR)</td><td align="left" colspan="1" rowspan="1">8.15 (6.3 - NR)</td></tr><tr><td align="left" colspan="1" rowspan="1">Increase</td><td align="left" colspan="1" rowspan="1">2.7 (2.7 - NR)</td><td char="." align="char" rowspan="2" colspan="1">0.2</td><td align="left" colspan="1" rowspan="1">25.7 (10.9 - NR)</td><td char="." align="char" rowspan="2" colspan="1">0.051</td><td align="left" colspan="1" rowspan="1">19.0 (11.0 - NR)</td><td char="." align="char" rowspan="2" colspan="1">
<bold>0.0041</bold>
</td><td align="left" colspan="1" rowspan="1">26.3 (25.1 - NR)</td><td char="." align="char" rowspan="2" colspan="1">
<bold>0.037</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Decrease</td><td align="left" colspan="1" rowspan="1">11.1 (5.3 - NR)</td><td align="left" colspan="1" rowspan="1">3.4 (3.3 - NR)</td><td align="left" colspan="1" rowspan="1">3.4 (2.7 - NR)</td><td align="left" colspan="1" rowspan="1">8.15 (6.3 - NR)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: PFS&#8201;=&#8201;progression-free survival, OS&#8201;=&#8201;overall survival, CI&#8201;=&#8201;confidence intervals, NR&#8201;=&#8201;not reached. Statistical significance level: <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05.</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec19"><title>Discussion</title><p id="Par78">As the use of ctDNA detection gains momentum in clinical settings, detection methods with high sensitivity, specificity and clinical applicability are needed. In this study, we present the development and validation of a 6-plex ddPCR for the detection of lung cancer.</p><p id="Par79">The analyses of lung tissue showed a significant difference in methylation levels between normal and tumour tissue for all five markers (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). While there was a significant difference in methylation level for all markers between benign and tumour tissue, several benign tissues exhibited moderate methylation of <italic toggle="yes">OTX1</italic>, unlike the normal lung tissue. This was also observed in the non-cancer plasma samples, where three samples had a much higher droplet count of <italic toggle="yes">OTX1</italic>. Increased cfDNA-concentration has been observed in patients with inflammatory and autoimmune diseases as a sign of immune responses and inflammatory tissue damage<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>. Our healthy control cohort used to establish LoB was chosen to include age-matched patients with comorbidities common in the lung cancer demographic, such as chronic obstructive lung disease, asthma, and other inflammatory lung diseases and rheumatic diseases, including rheumatoid arthritis. It is possible that the <italic toggle="yes">OTX1</italic> marker is not exclusively tumour-specific but also a marker of tissue breakdown and wider activation of the immune system. Due to this concern of false positives, we examined the diagnostic performance of a 5-plex model without <italic toggle="yes">OTX1</italic>. While we saw some differences in sensitivity and specificity, none were large enough to justify an exclusion of OTX1 from the 6-plex ddPCR.</p><p id="Par80">In this study, we examined two different methods for establishing a droplet-based LoB to explore their effects on the sensitivity and specificity of the test in a cohort of stage I-IV lung cancer patients (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>; Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). The results showed a clear preference for higher specificity for the method with a set&#8201;&#8805;&#8201;95% specificity, while Youden&#8217;s J statistics favoured sensitivity. For both methods, increasing the number of positive markers required to call a sample positive resulted in increasingly lower sensitivity and higher specificity. This has been previously explored by Henriksen et al. in a study examining over- and under-treatment with adjuvant chemotherapy in stage II-III colorectal cancer patients using ddPCR and different ctDNA-calling algorithms<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. They found that algorithms favouring specificity resulted in less overtreatment in low-risk patients, while under-treatment was seen in high-risk patients. Algorithms favouring sensitivity resulted in increased overtreatment in both patient groups. This highlights the trade-off between sensitivity and specificity, which should be considered based on the clinical setting.</p><p id="Par81">As expected, more patients with metastatic disease were ctDNA-positive compared to patients with non-metastatic disease (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Using a marker cut-off of at least two markers above established LoBs resulted in a ctDNA-positive percent for patients with non-metastatic disease of 38.7 and 46.8 for set&#8201;&#8805;&#8201;95% specificity and Youden&#8217;s J statistics, respectively. While the percentage was considerably higher for the metastatic patients, not all patients were ctDNA-positive (70.2% and 83.0%, respectively). Similar numbers have previously been reported in several studies in advanced lung cancer employing both NGS and ddPCR as detection methods<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. In addition to disease stage, histological subtypes were also shown to affect detection rates (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). The higher detection rate of SCLC could be attributed to several things. SCLC is more aggressive than NSCLC, and patients are often diagnosed with advanced stages of disease where the ctDNA levels are expected to be higher<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. This was also observed in our study, where all SCLC patients were stage III-IV. Additionally, SCLC has previously in one study been shown to have higher methylation levels in both lung cancer tissue and plasma samples of two differentially methylated regions in the genes <italic toggle="yes">HOXA9</italic> and <italic toggle="yes">RASSF1A</italic> compared to NSCLC, indicating that there might be a biological explanation as well<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Similarly, several studies have observed higher detection rates of SCC compared to AC in plasma<sup><xref ref-type="bibr" rid="CR37">37</xref>&#8211;<xref ref-type="bibr" rid="CR39">39</xref></sup>. While we observed similar detection rates for SCC and AC across all disease stages, a clear difference was evident in the patients with metastatic disease, where almost all SCC patients were ctDNA-positive when using both droplet cut-off methods. This has previously been observed in the TRACERx study, where early metastatic dissemination in NSCLC was studied<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. They suggested a low ctDNA-shedding phenotype of high-volume adenocarcinomas as a potential explanation. Of note, all the mentioned studies employed next-generation sequencing as a detection method. With our study, we show that similar trends are observed when performing ddPCR. The differences in ctDNA detection according to histological subtypes highlight that care should be taken when interpreting the ctDNA-status of a patient.</p><p id="Par82">Marker dynamics were examined in a cohort of mainly stage III-IV patients undergoing immunotherapy. In general, there was a high degree of congruence between the markers, with the majority of the samples having 4 or 5 markers of the same status (i.e. positive or negative) (Supplemental Table S4). Some of the incongruences can be explained by sampling stochasticity. If the level of ctDNA is low, detection of single markers is highly susceptible to subsampling of blood<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. It is also dependent on methodological variation of the whole analytical process, including blood sampling, DNA extraction, bisulfite conversion and droplet generation. Some variation between marker status is to be expected when the droplet count is close to LoB<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. In this study, 7/8 samples with only two positive markers demonstrated a low positive droplet count across all five assessed markers. The implementation of more markers in comparison to just one has the potential to mitigate subsampling and allow for the detection of ctDNA-positive samples that might otherwise have been missed.</p><p id="Par83">When comparing methylation ratios between baseline and after one or three treatment cycles, a high level of consensus was observed. No patients had both significantly increasing and decreasing markers according to the ctDNA-RECIST criteria. Kaplan Meier plots (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>) and log-rank tests (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>) showed statistically insignificant differences between most groups, although a significant increase in PFS and OS was observed when comparing patients in the <italic toggle="yes">Increase</italic> and <italic toggle="yes">Decrease</italic> group from baseline to the 4th treatment cycle. While the cohort was small and results should be interpreted very carefully, there was a trend towards an increased PFS and OS for patients with decreasing methylation ratios of all five markers compared to patients with stable values or increasing methylation levels.</p><p id="Par84">In conclusion, we present a robust methylation-specific 6-plex ddPCR for lung cancer detection and demonstrate that sensitivity and specificity are dependent on the methods used to establish marker LoBs. The developed ddPCR multiplex shows promise in various clinical settings. In early detection of lung cancer, the method may not be sensitive enough to identify all patients with cancer, but by optimising the method and the cut-off, it may be possible to develop a tool that helps identify patients, who should undergo further diagnostic evaluation. When monitoring palliative treatment of patients with metastatic disease, there is a need for reliable early indicators of treatment efficacy. The proposed method could enable early detection of treatment failure or response, thereby identifying patients that should continue current treatment or shift to other options. The rapid throughput of the method may facilitate decision-making within a clinically relevant time frame. In the future, its performance needs to be tested and validated in larger cohorts across different clinical contexts.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="41598_2025_15228_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><glossary id="AGS1"><title>Abbreviations</title><def-list><def-item><term>CT</term><def><p id="Par2">Computed tomography</p></def></def-item><def-item><term>MRD</term><def><p id="Par3">Minimal residual disease</p></def></def-item><def-item><term>ctDNA</term><def><p id="Par4">Circulating tumour DNA</p></def></def-item><def-item><term>CpG</term><def><p id="Par5">Cytosine-phosphate-Guanine dinucleotide</p></def></def-item><def-item><term>ddPCR</term><def><p id="Par6">Droplet digital polymerase chain reaction</p></def></def-item><def-item><term>TCGA</term><def><p id="Par7">The Cancer Genome Atlas</p></def></def-item><def-item><term>LAN</term><def><p id="Par8">Lung adjacent normal</p></def></def-item><def-item><term>LT</term><def><p id="Par9">Lung tumour</p></def></def-item><def-item><term>GDC</term><def><p id="Par10">NCI Genomic Data Commons</p></def></def-item><def-item><term>DMC</term><def><p id="Par11">Differentially methylated CpGs</p></def></def-item><def-item><term>RFE</term><def><p id="Par12">Recursive feature elimination</p></def></def-item><def-item><term>FFPE</term><def><p id="Par13">Formalin-fixed paraffin-embedded</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par14">Non-small cell lung cancer</p></def></def-item><def-item><term>cfDNA</term><def><p id="Par15">Cell free DNA</p></def></def-item><def-item><term>bp</term><def><p id="Par16">Base pairs</p></def></def-item><def-item><term>LoB</term><def><p id="Par17">Limit of blank</p></def></def-item><def-item><term>CI</term><def><p id="Par18">Confidence interval</p></def></def-item><def-item><term>SCLC</term><def><p id="Par19">Small cell lung cancer</p></def></def-item><def-item><term>SCC</term><def><p id="Par20">Squamous cell carcinoma</p></def></def-item><def-item><term>AC</term><def><p id="Par21">Adenocarcinoma</p></def></def-item><def-item><term>PFS</term><def><p id="Par22">Progression-free survival</p></def></def-item><def-item><term>OS</term><def><p id="Par23">Overall survival</p></def></def-item><def-item><term>NR</term><def><p id="Par24">Not reached</p></def></def-item></def-list></glossary><glossary id="AGS2"><title>Gene symbol (gene name approved by the HGNC)</title><def-list><def-item><term><italic toggle="yes">EMC7</italic></term><def><p id="Par26">ER membrane protein complex subunit 7</p></def></def-item><def-item><term><italic toggle="yes">ALB</italic></term><def><p id="Par27">Albumin</p></def></def-item><def-item><term><italic toggle="yes">HOXA9</italic></term><def><p id="Par28">Homeobox A9</p></def></def-item><def-item><term><italic toggle="yes">MCIDAS</italic></term><def><p id="Par29">Multiciliate differentiation and dna synthesis associated cell cycle protein</p></def></def-item><def-item><term><italic toggle="yes">OTX1</italic></term><def><p id="Par30">Orthodenticle homeobox 1</p></def></def-item><def-item><term><italic toggle="yes">SP9</italic></term><def><p id="Par31">Sp9 transcription factor</p></def></def-item><def-item><term><italic toggle="yes">TFAP2B</italic></term><def><p id="Par32">Transcription factor AP-2&#946;</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank Lone Hartmann Hansen, Pia Nielsen, and Tina Brandt Christensen for the laboratory work, and Luisa Matos do Canto for scientific discussions.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>CMJ: conceptualization, data curation, formal analysis, investigation, methodology, project administration, validation, visualization, writing &#8211; original draft preparation. PHH: data cura-tion, formal analysis, investigation, writing &#8211; review &amp; editing. SWCW: data curation, formal analysis, investigation, writing &#8211; review &amp; editing. JA: formal analysis, resources, writing &#8211; review &amp; editing. MMA: data curation, formal analysis, software, writing &#8211; review &amp; editing. CV: resources, writing &#8211; review &amp; editing. OH: resources, writing &#8211; review &amp; editing. TFH: conceptualization, funding acquisition, project administration, resources, supervision, writ-ing &#8211; review &amp; editing. RFA: conceptualization, investigation, methodology, project admin-istration, resources, supervision, validation, writing &#8211; review &amp; editing.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available from the corresponding author [ [rikke.fredslund.andersen@rsyd.dk](mailto: rikke.fredslund.andersen@rsyd.dk) ] upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par85">No external funding was secured for the study. No reagents, utensils, or equipment were donated to the project. CV received travel expenses from Stryker paid to the institution with no relevance to the present study. The other authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">GLOBOCAN. <italic toggle="yes">Cancer Today</italic>, (2024). <ext-link ext-link-type="uri" xlink:href="https://gco.iarc.fr/en">https://gco.iarc.fr/en</ext-link></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakobsen</surname><given-names>E</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>TR</given-names></name><name name-style="western"><surname>Green</surname><given-names>A</given-names></name></person-group><article-title>Mortality and survival of lung cancer in denmark: results from the Danish lung cancer group 2000&#8211;2012</article-title><source>Acta Oncol.</source><year>2016</year><volume>55 Suppl 2</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.3109/0284186x.2016.1150608</pub-id><pub-id pub-id-type="pmid">27056247</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Jakobsen, E., Rasmussen, T. R. &amp; Green, A. Mortality and survival of lung cancer in denmark: results from the Danish lung cancer group 2000&#8211;2012. <italic toggle="yes">Acta Oncol.</italic><bold>55 Suppl 2</bold>, 2&#8211;9. 10.3109/0284186x.2016.1150608 (2016).<pub-id pub-id-type="pmid">27056247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/0284186X.2016.1150608</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">NIH. <italic toggle="yes">SEER*Explorer: An interactive website for SEER cancer statistics</italic>, &lt; (2024). <ext-link ext-link-type="uri" xlink:href="https://seer.cancer.gov/statistics-network/">https://seer.cancer.gov/statistics-network/</ext-link></mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aberle</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Reduced lung-cancer mortality with low-dose computed tomographic screening</article-title><source>N Engl. J. Med.</source><year>2011</year><volume>365</volume><fpage>395</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1102873</pub-id><pub-id pub-id-type="pmid">21714641</pub-id><pub-id pub-id-type="pmcid">PMC4356534</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. <italic toggle="yes">N Engl. J. Med.</italic><bold>365</bold>, 395&#8211;409. 10.1056/NEJMoa1102873 (2011).<pub-id pub-id-type="pmid">21714641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1102873</pub-id><pub-id pub-id-type="pmcid">PMC4356534</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Koning</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Reduced Lung-Cancer mortality with volume CT screening in a randomized trial</article-title><source>N Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>503</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1911793</pub-id><pub-id pub-id-type="pmid">31995683</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">de Koning, H. J. et al. Reduced Lung-Cancer mortality with volume CT screening in a randomized trial. <italic toggle="yes">N Engl. J. Med.</italic><bold>382</bold>, 503&#8211;513. 10.1056/NEJMoa1911793 (2020).<pub-id pub-id-type="pmid">31995683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1911793</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moding</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced Non-Small cell lung cancer</article-title><source>Nat. Cancer</source><year>2020</year><volume>1</volume><fpage>176</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1038/s43018-019-0011-0</pub-id><pub-id pub-id-type="pmid">34505064</pub-id><pub-id pub-id-type="pmcid">PMC8425388</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Moding, E. J. et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced Non-Small cell lung cancer. <italic toggle="yes">Nat. Cancer</italic>. <bold>1</bold>, 176&#8211;183. 10.1038/s43018-019-0011-0 (2020).<pub-id pub-id-type="pmid">34505064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43018-019-0011-0</pub-id><pub-id pub-id-type="pmcid">PMC8425388</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerlinger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</article-title><source>N Engl. J. Med.</source><year>2012</year><volume>366</volume><fpage>883</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113205</pub-id><pub-id pub-id-type="pmid">22397650</pub-id><pub-id pub-id-type="pmcid">PMC4878653</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. <italic toggle="yes">N Engl. J. Med.</italic><bold>366</bold>, 883&#8211;892. 10.1056/NEJMoa1113205 (2012).<pub-id pub-id-type="pmid">22397650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1113205</pub-id><pub-id pub-id-type="pmcid">PMC4878653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kustanovich</surname><given-names>A</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>R</given-names></name><name name-style="western"><surname>Peretz</surname><given-names>T</given-names></name><name name-style="western"><surname>Grinshpun</surname><given-names>A</given-names></name></person-group><article-title>Life and death of Circulating cell-free DNA</article-title><source>Cancer Biol. Ther.</source><year>2019</year><volume>20</volume><fpage>1057</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1080/15384047.2019.1598759</pub-id><pub-id pub-id-type="pmid">30990132</pub-id><pub-id pub-id-type="pmcid">PMC6606043</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Kustanovich, A., Schwartz, R., Peretz, T. &amp; Grinshpun, A. Life and death of Circulating cell-free DNA. <italic toggle="yes">Cancer Biol. Ther.</italic><bold>20</bold>, 1057&#8211;1067. 10.1080/15384047.2019.1598759 (2019).<pub-id pub-id-type="pmid">30990132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15384047.2019.1598759</pub-id><pub-id pub-id-type="pmcid">PMC6606043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set</article-title><source>Ann. Oncol.</source><year>2021</year><volume>32</volume><fpage>1167</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.05.806</pub-id><pub-id pub-id-type="pmid">34176681</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Klein, E. A. et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. <italic toggle="yes">Ann. Oncol.</italic><bold>32</bold>, 1167&#8211;1177. 10.1016/j.annonc.2021.05.806 (2021).<pub-id pub-id-type="pmid">34176681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2021.05.806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Pardo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of Circulating tumor DNA testing before tissue diagnosis with time to treatment among patients with suspected advanced lung cancer: the ACCELERATE nonrandomized clinical trial</article-title><source>JAMA Netw. Open.</source><year>2023</year><volume>6</volume><fpage>e2325332</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.25332</pub-id><pub-id pub-id-type="pmid">37490292</pub-id><pub-id pub-id-type="pmcid">PMC10369925</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Garc&#237;a-Pardo, M. et al. Association of Circulating tumor DNA testing before tissue diagnosis with time to treatment among patients with suspected advanced lung cancer: the ACCELERATE nonrandomized clinical trial. <italic toggle="yes">JAMA Netw. Open.</italic><bold>6</bold>, e2325332. 10.1001/jamanetworkopen.2023.25332 (2023).<pub-id pub-id-type="pmid">37490292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.25332</pub-id><pub-id pub-id-type="pmcid">PMC10369925</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>M</given-names></name><etal/></person-group><article-title>Circulating tumor DNA as a prognostic biomarker in localized Non-small cell lung cancer</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><fpage>561598</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.561598</pub-id><pub-id pub-id-type="pmid">33042842</pub-id><pub-id pub-id-type="pmcid">PMC7523087</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Peng, M. et al. Circulating tumor DNA as a prognostic biomarker in localized Non-small cell lung cancer. <italic toggle="yes">Front. Oncol.</italic><bold>10</bold>, 561598. 10.3389/fonc.2020.561598 (2020).<pub-id pub-id-type="pmid">33042842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.561598</pub-id><pub-id pub-id-type="pmcid">PMC7523087</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gale</surname><given-names>D</given-names></name><etal/></person-group><article-title>Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA</article-title><source>PLOS ONE</source><year>2018</year><volume>13</volume><fpage>e0194630</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0194630</pub-id><pub-id pub-id-type="pmid">29547634</pub-id><pub-id pub-id-type="pmcid">PMC5856404</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Gale, D. et al. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. <italic toggle="yes">PLOS ONE</italic>. <bold>13</bold>, e0194630. 10.1371/journal.pone.0194630 (2018).<pub-id pub-id-type="pmid">29547634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0194630</pub-id><pub-id pub-id-type="pmcid">PMC5856404</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anagnostou</surname><given-names>V</given-names></name><etal/></person-group><article-title>CtDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>2559</fpage><lpage>2569</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02598-9</pub-id><pub-id pub-id-type="pmid">37814061</pub-id><pub-id pub-id-type="pmcid">PMC10579094</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Anagnostou, V. et al. CtDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. <italic toggle="yes">Nat. Med.</italic><bold>29</bold>, 2559&#8211;2569. 10.1038/s41591-023-02598-9 (2023).<pub-id pub-id-type="pmid">37814061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02598-9</pub-id><pub-id pub-id-type="pmcid">PMC10579094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>PA</given-names></name><name name-style="western"><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>The fundamental role of epigenetic events in cancer</article-title><source>Nat. Rev. Genet.</source><year>2002</year><volume>3</volume><fpage>415</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1038/nrg816</pub-id><pub-id pub-id-type="pmid">12042769</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Jones, P. A. &amp; Baylin, S. B. The fundamental role of epigenetic events in cancer. <italic toggle="yes">Nat. Rev. Genet.</italic><bold>3</bold>, 415&#8211;428. 10.1038/nrg816 (2002).<pub-id pub-id-type="pmid">12042769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrg816</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>SWC</given-names></name><etal/></person-group><article-title>The prognostic impact of Circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer</article-title><source>Transl Lung Cancer Res.</source><year>2021</year><volume>10</volume><fpage>855</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.21037/tlcr-20-826</pub-id><pub-id pub-id-type="pmid">33718027</pub-id><pub-id pub-id-type="pmcid">PMC7947403</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Wen, S. W. C. et al. The prognostic impact of Circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer. <italic toggle="yes">Transl Lung Cancer Res.</italic><bold>10</bold>, 855&#8211;865. 10.21037/tlcr-20-826 (2021).<pub-id pub-id-type="pmid">33718027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr-20-826</pub-id><pub-id pub-id-type="pmcid">PMC7947403</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Postel</surname><given-names>M</given-names></name><name name-style="western"><surname>Roosen</surname><given-names>A</given-names></name><name name-style="western"><surname>Laurent-Puig</surname><given-names>P</given-names></name><name name-style="western"><surname>Taly</surname><given-names>V</given-names></name><name name-style="western"><surname>Wang-Renault</surname><given-names>SF</given-names></name></person-group><article-title>Droplet-based digital PCR and next generation sequencing for monitoring Circulating tumor DNA: a cancer diagnostic perspective</article-title><source>Expert Rev. Mol. Diagn.</source><year>2018</year><volume>18</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1080/14737159.2018.1400384</pub-id><pub-id pub-id-type="pmid">29115895</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Postel, M., Roosen, A., Laurent-Puig, P., Taly, V. &amp; Wang-Renault, S. F. Droplet-based digital PCR and next generation sequencing for monitoring Circulating tumor DNA: a cancer diagnostic perspective. <italic toggle="yes">Expert Rev. Mol. Diagn.</italic><bold>18</bold>, 7&#8211;17. 10.1080/14737159.2018.1400384 (2018).<pub-id pub-id-type="pmid">29115895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737159.2018.1400384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA</article-title><source>Ann. Oncol.</source><year>2020</year><volume>31</volume><fpage>745</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.02.011</pub-id><pub-id pub-id-type="pmid">33506766</pub-id><pub-id pub-id-type="pmcid">PMC8274402</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <italic toggle="yes">Ann. Oncol.</italic><bold>31</bold>, 745&#8211;759. 10.1016/j.annonc.2020.02.011 (2020).<pub-id pub-id-type="pmid">33506766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2020.02.011</pub-id><pub-id pub-id-type="pmcid">PMC8274402</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>S</given-names></name><name name-style="western"><surname>&#216;gaard</surname><given-names>N</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Bramsen</surname><given-names>JB</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>CL</given-names></name></person-group><article-title>Enhanced performance of DNA methylation markers by simultaneous measurement of sense and antisense DNA strands after cytosine conversion</article-title><source>Clin. Chem.</source><year>2020</year><volume>66</volume><fpage>925</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1093/clinchem/hvaa100</pub-id><pub-id pub-id-type="pmid">32460325</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Jensen, S., &#216;gaard, N., Nielsen, H. J., Bramsen, J. B. &amp; Andersen, C. L. Enhanced performance of DNA methylation markers by simultaneous measurement of sense and antisense DNA strands after cytosine conversion. <italic toggle="yes">Clin. Chem.</italic><bold>66</bold>, 925&#8211;933. 10.1093/clinchem/hvaa100 (2020).<pub-id pub-id-type="pmid">32460325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/clinchem/hvaa100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Nunes, S. P. et al. Subtyping lung cancer using DNA methylation in liquid biopsies. <italic toggle="yes">J. Clin. Med.</italic><bold>8</bold>10.3390/jcm8091500 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm8091500</pub-id><pub-id pub-id-type="pmcid">PMC6780554</pub-id><pub-id pub-id-type="pmid">31546933</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faaborg</surname><given-names>L</given-names></name><etal/></person-group><article-title>Analysis of HOXA9 methylated ctdna in ovarian cancer using sense-antisense measurement</article-title><source>Clin. Chim. Acta</source><year>2021</year><volume>522</volume><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2021.08.020</pub-id><pub-id pub-id-type="pmid">34419462</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Faaborg, L. et al. Analysis of HOXA9 methylated ctdna in ovarian cancer using sense-antisense measurement. <italic toggle="yes">Clin. Chim. Acta</italic>. <bold>522</bold>, 152&#8211;157. 10.1016/j.cca.2021.08.020 (2021).<pub-id pub-id-type="pmid">34419462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2021.08.020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Research electronic data capture (REDCap)&#8212;A metadata-driven methodology and workflow process for providing translational research informatics support</article-title><source>J. Biomed. Inform.</source><year>2009</year><volume>42</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.jbi.2008.08.010</pub-id><pub-id pub-id-type="pmid">18929686</pub-id><pub-id pub-id-type="pmcid">PMC2700030</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Harris, P. A. et al. Research electronic data capture (REDCap)&#8212;A metadata-driven methodology and workflow process for providing translational research informatics support. <italic toggle="yes">J. Biomed. Inform.</italic><bold>42</bold>, 377&#8211;381. 10.1016/j.jbi.2008.08.010 (2009).<pub-id pub-id-type="pmid">18929686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbi.2008.08.010</pub-id><pub-id pub-id-type="pmcid">PMC2700030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>PA</given-names></name><etal/></person-group><article-title>The REDCap consortium: Building an international community of software platform partners</article-title><source>J. Biomed. Inform.</source><year>2019</year><volume>95</volume><fpage>103208</fpage><pub-id pub-id-type="doi">10.1016/j.jbi.2019.103208</pub-id><pub-id pub-id-type="pmid">31078660</pub-id><pub-id pub-id-type="pmcid">PMC7254481</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Harris, P. A. et al. The REDCap consortium: Building an international community of software platform partners. <italic toggle="yes">J. Biomed. Inform.</italic><bold>95</bold>, 103208. 10.1016/j.jbi.2019.103208 (2019).<pub-id pub-id-type="pmid">31078660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbi.2019.103208</pub-id><pub-id pub-id-type="pmcid">PMC7254481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallisgaard</surname><given-names>N</given-names></name><name name-style="western"><surname>Spindler</surname><given-names>KL</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>RF</given-names></name><name name-style="western"><surname>Brandslund</surname><given-names>I</given-names></name><name name-style="western"><surname>Jakobsen</surname><given-names>A</given-names></name></person-group><article-title>Controls to validate plasma samples for cell free DNA quantification</article-title><source>Clin. Chim. Acta</source><year>2015</year><volume>446</volume><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2015.04.015</pub-id><pub-id pub-id-type="pmid">25896958</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Pallisgaard, N., Spindler, K. L., Andersen, R. F., Brandslund, I. &amp; Jakobsen, A. Controls to validate plasma samples for cell free DNA quantification. <italic toggle="yes">Clin. Chim. Acta</italic>. <bold>446</bold>, 141&#8211;146. 10.1016/j.cca.2015.04.015 (2015).<pub-id pub-id-type="pmid">25896958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2015.04.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>T</given-names></name><etal/></person-group><article-title>NCBI GEO: archive for functional genomics data sets&#8211;update</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><fpage>D991</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1193</pub-id><pub-id pub-id-type="pmid">23193258</pub-id><pub-id pub-id-type="pmcid">PMC3531084</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Barrett, T. et al. NCBI GEO: archive for functional genomics data sets&#8211;update. <italic toggle="yes">Nucleic Acids Res.</italic><bold>41</bold>, D991&#8211;995. 10.1093/nar/gks1193 (2013).<pub-id pub-id-type="pmid">23193258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gks1193</pub-id><pub-id pub-id-type="pmcid">PMC3531084</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoshita</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sex differences of leukocytes DNA methylation adjusted for estimated cellular proportions</article-title><source>Biol. Sex. Differ.</source><year>2015</year><volume>6</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s13293-015-0029-7</pub-id><pub-id pub-id-type="pmid">26113971</pub-id><pub-id pub-id-type="pmcid">PMC4480901</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Inoshita, M. et al. Sex differences of leukocytes DNA methylation adjusted for estimated cellular proportions. <italic toggle="yes">Biol. Sex. Differ.</italic><bold>6</bold>, 11. 10.1186/s13293-015-0029-7 (2015).<pub-id pub-id-type="pmid">26113971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13293-015-0029-7</pub-id><pub-id pub-id-type="pmcid">PMC4480901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitaksalee</surname><given-names>R</given-names></name><etal/></person-group><article-title>Differential CpG DNA methylation in peripheral Na&#239;ve CD4(+) T-cells in early rheumatoid arthritis patients</article-title><source>Clin. Epigenetics</source><year>2020</year><volume>12</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s13148-020-00837-1</pub-id><pub-id pub-id-type="pmid">32264938</pub-id><pub-id pub-id-type="pmcid">PMC7137446</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Pitaksalee, R. et al. Differential CpG DNA methylation in peripheral Na&#239;ve CD4(+) T-cells in early rheumatoid arthritis patients. <italic toggle="yes">Clin. Epigenetics</italic>. <bold>12</bold>, 54. 10.1186/s13148-020-00837-1 (2020).<pub-id pub-id-type="pmid">32264938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13148-020-00837-1</pub-id><pub-id pub-id-type="pmcid">PMC7137446</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grossman</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Toward a shared vision for cancer genomic data</article-title><source>N Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>1109</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1607591</pub-id><pub-id pub-id-type="pmid">27653561</pub-id><pub-id pub-id-type="pmcid">PMC6309165</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Grossman, R. L. et al. Toward a shared vision for cancer genomic data. <italic toggle="yes">N Engl. J. Med.</italic><bold>375</bold>, 1109&#8211;1112. 10.1056/NEJMp1607591 (2016).<pub-id pub-id-type="pmid">27653561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp1607591</pub-id><pub-id pub-id-type="pmcid">PMC6309165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aryee</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Minfi: a flexible and comprehensive bioconductor package for the analysis of infinium DNA methylation microarrays</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>1363</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu049</pub-id><pub-id pub-id-type="pmid">24478339</pub-id><pub-id pub-id-type="pmcid">PMC4016708</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Aryee, M. J. et al. Minfi: a flexible and comprehensive bioconductor package for the analysis of infinium DNA methylation microarrays. <italic toggle="yes">Bioinformatics</italic><bold>30</bold>, 1363&#8211;1369. 10.1093/bioinformatics/btu049 (2014).<pub-id pub-id-type="pmid">24478339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btu049</pub-id><pub-id pub-id-type="pmcid">PMC4016708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Lef&#232;vre, A. C. et al. The clinical value of measuring Circulating HPV DNA during Chemo-Radiotherapy in squamous cell carcinoma of the anus. <italic toggle="yes">Cancers (Basel)</italic>. 13. 10.3390/cancers13102451 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13102451</pub-id><pub-id pub-id-type="pmcid">PMC8158133</pub-id><pub-id pub-id-type="pmid">34070045</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ar&#225;nyi</surname><given-names>T</given-names></name><name name-style="western"><surname>Tusn&#225;dy</surname><given-names>GE</given-names></name><name name-style="western"><surname>BiSearch</surname></name></person-group><article-title>ePCR tool for native or bisulfite-treated genomic template</article-title><source>Methods Mol. Biol.</source><year>2007</year><volume>402</volume><fpage>385</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1007/978-1-59745-528-2_20</pub-id><pub-id pub-id-type="pmid">17951807</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ar&#225;nyi, T., Tusn&#225;dy, G. E. &amp; BiSearch ePCR tool for native or bisulfite-treated genomic template. <italic toggle="yes">Methods Mol. Biol.</italic><bold>402</bold>, 385&#8211;402. 10.1007/978-1-59745-528-2_20 (2007).<pub-id pub-id-type="pmid">17951807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-59745-528-2_20</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Youden, W. J. Index for rating diagnostic tests. <italic toggle="yes">Cancer</italic><bold>3</bold>, 32&#8211;35. https://doi.org/10.1002/1097-0142(1950)3:1&lt;32::aid-cncr2820030106&gt;3.0.co;2-3 (1950).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(1950)3:1&lt;32::aid-cncr2820030106&gt;3.0.co;2-3</pub-id><pub-id pub-id-type="pmid">15405679</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakobsen</surname><given-names>AKM</given-names></name><name name-style="western"><surname>Spindler</surname><given-names>KG</given-names></name></person-group><article-title>ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology</article-title><source>Eur. J. Cancer</source><year>2023</year><volume>180</volume><fpage>180</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2022.11.039</pub-id><pub-id pub-id-type="pmid">36610263</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Jakobsen, A. K. M. &amp; Spindler, K. G. ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology. <italic toggle="yes">Eur. J. Cancer</italic>. <bold>180</bold>, 180&#8211;183. 10.1016/j.ejca.2022.11.039 (2023).<pub-id pub-id-type="pmid">36610263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2022.11.039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spindler</surname><given-names>KG</given-names></name><name name-style="western"><surname>Jakobsen</surname><given-names>A</given-names></name></person-group><article-title>Circulating tumor DNA: response evaluation criteria in solid Tumors - can we RECIST? Focus on colorectal cancer</article-title><source>Ther. Adv. Med. Oncol.</source><year>2023</year><volume>15</volume><fpage>17588359231171580</fpage><pub-id pub-id-type="doi">10.1177/17588359231171580</pub-id><pub-id pub-id-type="pmid">37152423</pub-id><pub-id pub-id-type="pmcid">PMC10154995</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Spindler, K. G. &amp; Jakobsen, A. Circulating tumor DNA: response evaluation criteria in solid Tumors - can we RECIST? Focus on colorectal cancer. <italic toggle="yes">Ther. Adv. Med. Oncol.</italic><bold>15</bold>, 17588359231171580. 10.1177/17588359231171580 (2023).<pub-id pub-id-type="pmid">37152423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17588359231171580</pub-id><pub-id pub-id-type="pmcid">PMC10154995</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comprehensive human cell-type methylation atlas reveals origins of Circulating cell-free DNA in health and disease</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>5068</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-07466-6</pub-id><pub-id pub-id-type="pmid">30498206</pub-id><pub-id pub-id-type="pmcid">PMC6265251</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Moss, J. et al. Comprehensive human cell-type methylation atlas reveals origins of Circulating cell-free DNA in health and disease. <italic toggle="yes">Nat. Commun.</italic><bold>9</bold>, 5068. 10.1038/s41467-018-07466-6 (2018).<pub-id pub-id-type="pmid">30498206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-07466-6</pub-id><pub-id pub-id-type="pmcid">PMC6265251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henriksen</surname><given-names>TV</given-names></name><etal/></person-group><article-title>Unraveling the potential clinical utility of Circulating tumor DNA detection in colorectal cancer - evaluation in a nationwide Danish cohort</article-title><source>Ann. Oncol.</source><year>2023</year><pub-id pub-id-type="doi">10.1016/j.annonc.2023.11.009</pub-id><pub-id pub-id-type="pmid">37992872</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Henriksen, T. V. et al. Unraveling the potential clinical utility of Circulating tumor DNA detection in colorectal cancer - evaluation in a nationwide Danish cohort. <italic toggle="yes">Ann. Oncol.</italic>10.1016/j.annonc.2023.11.009 (2023).<pub-id pub-id-type="pmid">37992872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2023.11.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assaf</surname><given-names>ZJF</given-names></name><etal/></person-group><article-title>A longitudinal Circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>859</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02226-6</pub-id><pub-id pub-id-type="pmid">36928816</pub-id><pub-id pub-id-type="pmcid">PMC10115641</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Assaf, Z. J. F. et al. A longitudinal Circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. <italic toggle="yes">Nat. Med.</italic><bold>29</bold>, 859&#8211;868. 10.1038/s41591-023-02226-6 (2023).<pub-id pub-id-type="pmid">36928816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02226-6</pub-id><pub-id pub-id-type="pmcid">PMC10115641</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhuri</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Early detection of molecular residual disease in localized lung cancer by Circulating tumor DNA profiling</article-title><source>Cancer Discov</source><year>2017</year><volume>7</volume><fpage>1394</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.Cd-17-0716</pub-id><pub-id pub-id-type="pmid">28899864</pub-id><pub-id pub-id-type="pmcid">PMC5895851</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Chaudhuri, A. A. et al. Early detection of molecular residual disease in localized lung cancer by Circulating tumor DNA profiling. <italic toggle="yes">Cancer Discov</italic>. <bold>7</bold>, 1394&#8211;1403. 10.1158/2159-8290.Cd-17-0716 (2017).<pub-id pub-id-type="pmid">28899864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-17-0716</pub-id><pub-id pub-id-type="pmcid">PMC5895851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>HT</given-names></name><etal/></person-group><article-title>Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer</article-title><source>Ann. Oncol.</source><year>2024</year><volume>35</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2023.11.008</pub-id><pub-id pub-id-type="pmid">37992871</pub-id><pub-id pub-id-type="pmcid">PMC11233158</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Tran, H. T. et al. Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer. <italic toggle="yes">Ann. Oncol.</italic><bold>35</bold>, 183&#8211;189. 10.1016/j.annonc.2023.11.008 (2024).<pub-id pub-id-type="pmid">37992871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2023.11.008</pub-id><pub-id pub-id-type="pmcid">PMC11233158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gale</surname><given-names>D</given-names></name><etal/></person-group><article-title>Residual ctdna after treatment predicts early relapse in patients with early-stage non-small cell lung cancer</article-title><source>Ann. Oncol.</source><year>2022</year><volume>33</volume><fpage>500</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.02.007</pub-id><pub-id pub-id-type="pmid">35306155</pub-id><pub-id pub-id-type="pmcid">PMC9067454</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Gale, D. et al. Residual ctdna after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. <italic toggle="yes">Ann. Oncol.</italic><bold>33</bold>, 500&#8211;510. 10.1016/j.annonc.2022.02.007 (2022).<pub-id pub-id-type="pmid">35306155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2022.02.007</pub-id><pub-id pub-id-type="pmcid">PMC9067454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbosh</surname><given-names>C</given-names></name><etal/></person-group><article-title>Tracking early lung cancer metastatic dissemination in tracerx using ctdna</article-title><source>Nature</source><year>2023</year><volume>616</volume><fpage>553</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05776-4</pub-id><pub-id pub-id-type="pmid">37055640</pub-id><pub-id pub-id-type="pmcid">PMC7614605</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Abbosh, C. et al. Tracking early lung cancer metastatic dissemination in tracerx using ctdna. <italic toggle="yes">Nature</italic><bold>616</bold>, 553&#8211;562. 10.1038/s41586-023-05776-4 (2023).<pub-id pub-id-type="pmid">37055640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-05776-4</pub-id><pub-id pub-id-type="pmcid">PMC7614605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzonev</surname><given-names>S</given-names></name></person-group><article-title>Fundamentals of counting statistics in digital PCR: I just measured two target Copies-What does it mean??</article-title><source>Methods Mol. Biol.</source><year>2018</year><volume>1768</volume><fpage>25</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7778-9_3</pub-id><pub-id pub-id-type="pmid">29717436</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Tzonev, S. Fundamentals of counting statistics in digital PCR: I just measured two target Copies-What does it mean?? <italic toggle="yes">Methods Mol. Biol.</italic><bold>1768</bold>, 25&#8211;43. 10.1007/978-1-4939-7778-9_3 (2018).<pub-id pub-id-type="pmid">29717436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-7778-9_3</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>